Millions of customers have explored their genome with 23andMe. But when the company started in 2006, the idea of consumer DNA testing was heresy to the medical establishment. The FDA even ordered 23andMe to stop selling its health testing product. The company persevered to make allies out of adversaries, and became the only FDA-approved product on the market. Learn how 23andMe defined the DNA testing category, how it found product-market fit, and used its growing scale to enter the massive new field of drug discovery.


Highlights
Why Anne started 23andMe and the company's "Why Now" [1:34]
Finding the market for genetic testing [5:12]
A challenge from regulators [7:44]
To fold, to fight or to comply? [12:32]
Gathering the right team for the new job ahead [14:06]
The pivot to therapeutics [18:32]
Reigniting growth amid privacy concerns and tapering sales [27:44]
Yet another pivot, this time to telehealth [30:03]
Lessons learned from 23andMe's crucible moments [32:24]


Anne Wojcicki
Anne Wojcicki is the founder and CEO of 23andMe. She also co-founded the Breakthrough Prize, where she sits on the board. Previously she spent a decade investing in biotech companies.

Richard Scheller
Richard Scheller sits on the board of 23andMe, and founded the company’s research and therapeutic development team. Prior to joining 23andMe, he was an executive at Genentech and Roche.